Charles McDermott
Director/Board Member at EQUILLIUM, INC.
Net worth: 43 076 $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Daniel Bradbury | M | 62 | 7 years | |
| Bruce Steel | M | 57 | 7 years | |
| Mark Iwicki | M | 57 | 9 years | |
| James R. Appleman | M | 67 |
Primmune Therapeutics, Inc.
 Primmune Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Primmune Therapeutics, Inc. develops small molecules, orally administered toll-like receptor for cancer immunotherapy and tumors. The firm offers treatment and prevention of viral infections. The company was founded by Paulo Rangel, James Appleman, and Stephen Webber in October, 2017 and is headquartered in San Diego, CA. | 7 years |
| Stephen Connelly | M | 42 | 7 years | |
| Paulo S. Rangel | M | - |
Primmune Therapeutics, Inc.
Primmune Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Primmune Therapeutics, Inc. develops small molecules, orally administered toll-like receptor for cancer immunotherapy and tumors. The firm offers treatment and prevention of viral infections. The company was founded by Paulo Rangel, James Appleman, and Stephen Webber in October, 2017 and is headquartered in San Diego, CA. | 7 years |
| Howard Rosen | M | 66 | 10 years | |
| Mary Reumuth | F | 48 | 10 years | |
| Bala S. Manian | M | 77 | 7 years | |
| Birgit Zech | M | - |
Anavo Therapeutics BV
 Anavo Therapeutics BV BiotechnologyHealth Technology Anavo Therapeutics BV is a Dutch company that specializes in developing first-in-class therapeutic programs for several indications in oncology. The company is based in Leiden, Netherlands. The company has attracted world-leading scientific expertise in phosphatase-driven disease biology and drug discovery to unlock the full potential of phosphatase-targeted allosteric modulators. Anavo is the first company to systematically drug phosphatases, a rich target space previously considered undruggable for decades. Anavo is backed by blue-chip investors m ventures, inkef capital, taiho ventures, mrl ventures fund, and bioqube ventures. The company was founded by Claus Schalper, Birgit Zech, Gerhard Müller. Birgit Zech has been the CEO since incorporation. | 3 years |
| Michael Moore | M | - | 4 years | |
| Mark Pruzanski | M | 56 | 6 years | |
| Yu Katherine Xu | M | 52 | 3 years | |
| Claus Schalper | M | 54 |
Anavo Therapeutics BV
Anavo Therapeutics BV BiotechnologyHealth Technology Anavo Therapeutics BV is a Dutch company that specializes in developing first-in-class therapeutic programs for several indications in oncology. The company is based in Leiden, Netherlands. The company has attracted world-leading scientific expertise in phosphatase-driven disease biology and drug discovery to unlock the full potential of phosphatase-targeted allosteric modulators. Anavo is the first company to systematically drug phosphatases, a rich target space previously considered undruggable for decades. Anavo is backed by blue-chip investors m ventures, inkef capital, taiho ventures, mrl ventures fund, and bioqube ventures. The company was founded by Claus Schalper, Birgit Zech, Gerhard Müller. Birgit Zech has been the CEO since incorporation. | - |
| Martha Demski | F | 71 | 6 years | |
| Barbara Troupin | M | 56 | 2 years | |
| Stephen E Webber | M | - |
Primmune Therapeutics, Inc.
Primmune Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Primmune Therapeutics, Inc. develops small molecules, orally administered toll-like receptor for cancer immunotherapy and tumors. The firm offers treatment and prevention of viral infections. The company was founded by Paulo Rangel, James Appleman, and Stephen Webber in October, 2017 and is headquartered in San Diego, CA. | 7 years |
| Maple Fung | M | - | 4 years | |
| Cherie Ng | F | - | - | |
| Joel Rothman | M | 55 | 6 years | |
| Todd Harris | M | 44 |
Primmune Therapeutics, Inc.
Primmune Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Primmune Therapeutics, Inc. develops small molecules, orally administered toll-like receptor for cancer immunotherapy and tumors. The firm offers treatment and prevention of viral infections. The company was founded by Paulo Rangel, James Appleman, and Stephen Webber in October, 2017 and is headquartered in San Diego, CA. | 5 years |
| Christine Zedelmayer | F | 54 | 6 years | |
| Scott Morenstein | M | 48 |
Primmune Therapeutics, Inc.
Primmune Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Primmune Therapeutics, Inc. develops small molecules, orally administered toll-like receptor for cancer immunotherapy and tumors. The firm offers treatment and prevention of viral infections. The company was founded by Paulo Rangel, James Appleman, and Stephen Webber in October, 2017 and is headquartered in San Diego, CA. | - |
| Matthew R. Ritter | M | - | - | |
| Andrew Rubinstein | M | - |
Primmune Therapeutics, Inc.
Primmune Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Primmune Therapeutics, Inc. develops small molecules, orally administered toll-like receptor for cancer immunotherapy and tumors. The firm offers treatment and prevention of viral infections. The company was founded by Paulo Rangel, James Appleman, and Stephen Webber in October, 2017 and is headquartered in San Diego, CA. | - |
| Amir Nashat | M | 51 |
Primmune Therapeutics, Inc.
Primmune Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Primmune Therapeutics, Inc. develops small molecules, orally administered toll-like receptor for cancer immunotherapy and tumors. The firm offers treatment and prevention of viral infections. The company was founded by Paulo Rangel, James Appleman, and Stephen Webber in October, 2017 and is headquartered in San Diego, CA. | - |
| Richard Daniels | M | - |
Primmune Therapeutics, Inc.
Primmune Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Primmune Therapeutics, Inc. develops small molecules, orally administered toll-like receptor for cancer immunotherapy and tumors. The firm offers treatment and prevention of viral infections. The company was founded by Paulo Rangel, James Appleman, and Stephen Webber in October, 2017 and is headquartered in San Diego, CA. | 3 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Herb Boyer | M | 87 | 19 years | |
| Vivid Sehgal | M | 56 | 8 years | |
| Sanjiv Patel | M | 50 | 11 years | |
| Stephen J. Ryan | M | 83 | 11 years | |
| Dawn Hudson | F | 66 | 6 years | |
| David Berk | M | 45 | 6 years | |
| Louis Lavigne | M | 75 | 10 years | |
| Robert Alexander Ingram | M | 81 | 7 years | |
| Dolca Thomas | M | 53 | 1 years | |
| David Hollander | M | 50 | - | |
| Matthew Joseph Maletta | M | 52 | - | |
| Samuel Gesten | M | 62 | 2 years | |
| Raj Shah | M | 46 | 6 years | |
| Peter John McDonnell | M | 66 | 7 years | |
| Abhay Joshi | M | 61 | 5 years | |
| Deborah Dunsire | M | 61 | 9 years | |
| Paulina Hill | M | 42 | 1 years | |
| James R. Beery | M | 83 |
deCODE genetics, Inc.
 deCODE genetics, Inc. Pharmaceuticals: GenericHealth Technology deCODE genetics, Inc. is a bio-pharmaceutical company. It developing and marketing products to improve the treatment, diagnosis and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. The company was founded by Kari Stefansson and Jeffrey Gulcher in August 1996 and is headquartered in Reykjavík, Iceland. | 6 years |
| Lance Thibault | M | 58 |
deCODE genetics, Inc.
deCODE genetics, Inc. Pharmaceuticals: GenericHealth Technology deCODE genetics, Inc. is a bio-pharmaceutical company. It developing and marketing products to improve the treatment, diagnosis and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. The company was founded by Kari Stefansson and Jeffrey Gulcher in August 1996 and is headquartered in Reykjavík, Iceland. | 9 years |
| Leonard Schaeffer | M | 78 | 18 years | |
| Gregory Grunberg | M | 51 | 7 years | |
| Louis T. Rosso | M | - | 16 years | |
| John Hood | M | - |
Impact Biomedicines, Inc.
 Impact Biomedicines, Inc. Medical SpecialtiesHealth Technology Impact Biomedicines, Inc. engages in the development of cancer treatments. It engages in the development of fedratinib, a potent and selective oral molecule JAK2 kinase inhibitor for the treatment of myelofibrosis and polycythemia vera. The company was founded by John Hood, Catriona Jamieson and Raghu Saripalli in 2016 and is headquartered in San Diego, CA. | 2 years |
| Michele LaRussa | F | 54 | - | |
| F. Ball | M | 68 | 16 years | |
| Timothy Kirk Andrews | M | 45 | 5 years | |
| David Moatazedi | M | 46 | 5 years | |
| Paul L. Jenkinson | M | 64 | 9 years | |
| Jason Keyes | M | 53 | 6 years | |
| Dennis Huang | M | 59 | 7 years | |
| Yehia Hashad | M | 57 | 9 years | |
| Aziz Mottiwala | M | 46 | 11 years | |
| Vincent Kosewski | M | - | - | |
| Gabriella Szekely | M | - | 7 years | |
| Jane Wolf | F | - | 1 years | |
| Alisa Lask | F | 53 | 3 years | |
| Gary Charbonneau | M | - | 11 years | |
| Dianne Whitfield | F | 47 | 12 years | |
| Nancy Grygiel | F | 56 | 4 years | |
| Susan L. Coultas | M | - | 6 years | |
| June Bray | F | 70 | 12 years | |
| Christopher Nardo | M | 59 | 5 years | |
| Rajkumar Narayanan | M | - | 9 years | |
| Alexandre Kaoukhov | M | - | 7 years | |
| Karen Smith | M | 56 | 4 years | |
| Preston Klassen | M | 55 | - | |
| Jonathan Edwards | M | 40 |
Impact Biomedicines, Inc.
Impact Biomedicines, Inc. Medical SpecialtiesHealth Technology Impact Biomedicines, Inc. engages in the development of cancer treatments. It engages in the development of fedratinib, a potent and selective oral molecule JAK2 kinase inhibitor for the treatment of myelofibrosis and polycythemia vera. The company was founded by John Hood, Catriona Jamieson and Raghu Saripalli in 2016 and is headquartered in San Diego, CA. | 1 years |
| Kevin Bitterman | M | 47 | - | |
| Jacqueline J. Schiavo | F | 75 | 25 years | |
| Patricia Walker | M | 64 | 1 years | |
| Timothy Proctor | M | 74 | 2 years | |
| Eric Carter | M | 72 | 4 years | |
| Scott Sherman | M | 57 | - | |
| Jonathan Wesley Porter | M | 54 | 2 years | |
| Karen Osar | F | 74 | 7 years | |
| J. Neal Armstrong | M | 85 |
deCODE genetics, Inc.
deCODE genetics, Inc. Pharmaceuticals: GenericHealth Technology deCODE genetics, Inc. is a bio-pharmaceutical company. It developing and marketing products to improve the treatment, diagnosis and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. The company was founded by Kari Stefansson and Jeffrey Gulcher in August 1996 and is headquartered in Reykjavík, Iceland. | 7 years |
| David A. Eiznhamer | M | 59 |
deCODE genetics, Inc.
deCODE genetics, Inc. Pharmaceuticals: GenericHealth Technology deCODE genetics, Inc. is a bio-pharmaceutical company. It developing and marketing products to improve the treatment, diagnosis and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. The company was founded by Kari Stefansson and Jeffrey Gulcher in August 1996 and is headquartered in Reykjavík, Iceland. | 1 years |
| Arnold A. Pinkston | M | 65 | 4 years | |
| Dianne Dyer-Bruggeman | F | 74 | 2 years | |
| Niv Edward Caviar | M | 56 | 5 years | |
| Kimberly D. Hunsicker | F | - | 2 years | |
| Deepak Chadha | M | 54 | 7 years | |
| Peter A. Kresel | M | 80 | - | |
| William F. Daly | M | - | 2 years | |
| Richard A. Leach | M | - |
deCODE genetics, Inc.
deCODE genetics, Inc. Pharmaceuticals: GenericHealth Technology deCODE genetics, Inc. is a bio-pharmaceutical company. It developing and marketing products to improve the treatment, diagnosis and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. The company was founded by Kari Stefansson and Jeffrey Gulcher in August 1996 and is headquartered in Reykjavík, Iceland. | 5 years |
| Daniel C. Siu | M | - |
deCODE genetics, Inc.
deCODE genetics, Inc. Pharmaceuticals: GenericHealth Technology deCODE genetics, Inc. is a bio-pharmaceutical company. It developing and marketing products to improve the treatment, diagnosis and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. The company was founded by Kari Stefansson and Jeffrey Gulcher in August 1996 and is headquartered in Reykjavík, Iceland. | 6 years |
| Karen Potts | M | 61 | 3 years | |
| Handel E. Evans | M | - | 18 years | |
| Chen-Ming Yu | M | 50 | 1 years | |
| Crystal Muilenburg | F | 45 | 11 years | |
| Richard P. M. Glover | M | 57 | 5 years | |
| Krishna R. Polu | M | 50 | 2 years | |
| Lars Kielhorn | M | - | 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 92 | 92.00% |
| Iceland | 6 | 6.00% |
| Netherlands | 2 | 2.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Charles McDermott
- Personal Network
